PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer

Roman M. Chabanon, … , Christopher J. Lord, Sophie Postel-Vinay

*J Clin Invest.* 2019;129(3):1211-1228. [https://doi.org/10.1172/JCI123319](https://doi.org/10.1172/JCI123319).

The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA repair deficiencies such as those caused by *BRCA1* mutations or *ERCC1* defects. Using isogenic cell lines and patient-derived samples, we showed that ERCC1-defective non–small cell lung cancer (NSCLC) cells exhibit an enhanced type I IFN transcriptomic signature and that low ERCC1 expression correlates with increased lymphocytic infiltration. We demonstrated that clinical PARPi, including olaparib and rucaparib, have cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC and BRCA1-defective triple-negative breast cancer (TNBC) cells. Mechanistically, PARPi generated cytoplasmic chromatin fragments with characteristics of micronuclei; these were found to activate cGAS/STING, downstream type I IFN signaling, and CCL5 secretion. Importantly, these effects were suppressed in *PARP1*-null TNBC cells, suggesting that this phenotype resulted from an on-target effect of PARPi on PARP1. PARPi also potentiated IFN-γ–induced PD-L1 expression in NSCLC cell lines and in fresh patient tumor cells; this effect was enhanced in ERCC1-deficient contexts. Our data provide a preclinical rationale for using PARPi as immunomodulatory agents in appropriately molecularly selected populations.

Find the latest version:

[http://jci.me/123319/pdf](http://jci.me/123319/pdf)
PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient small cell lung cancer

Roman M. Chabanon,1,2,3,4 Gareth Muirhead,2 Dragomir B. Krastev,1,4 Julien Adam,2 Daphné Morel,1,2 Marlène Garrido,2 Andrew Lamb,3 Clémence Hénon,1,2 Nicolas Dorvault,1 Mathieu Rownan,1,4 Rebecca Marlow,7 Ilirjana Bajrami,3,4 Marta Llorca Cardenosa,3,4,8 Asha Konde,3,4 Benjamin Besse,1,9 Alan Ashworth,10 Stephen J. Pettitt,3,4 Syed Haider,3 Aurélien Marabelle,6,11 Andrew N.J. Tutt,3,7 Jean-Charles Soria,1 Christopher J. Lord,1,4 and Sophie Postel-Vinay1,2,11

1Université Paris Saclay, Université Paris-Sud, Faculté de médecine, Le Kremlin Bicêtre, Paris, France. 2ATIP-Avenir group, Inserm U981, Gustave Roussy, Villejuif, France. 3The Breast Cancer Now Toby Robins Breast Cancer Research Centre and CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom. 4Sage Bionetworks, Seattle, Washington, USA. 5Inserm U1015, Gustave Roussy, Villejuif, France. 6The Breast Cancer Now Research Unit, King’s College London, London, United Kingdom. 7Biomedical Research Institute INCLIVA, Hospital Clinico Universitario Valencia, University of Valencia, Valencia, Spain. 8Department of Medical Oncology, Gustave Roussy, Villejuif, France. 9UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA. 10Département d’Innovations Thérapeutiques et Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.

The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA repair deficiencies such as those caused by BRCA1 mutations or ERCC1 defects. Using isogenic cell lines and patient-derived samples, we showed that ERCC1-defective non–small cell lung cancer (NSCLC) cells exhibit an enhanced type I IFN transcriptional signature and that low ERCC1 expression correlates with increased lymphocytic infiltration. We demonstrated that clinical PARPi, including olaparib andrucaparib, have cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC and BRCA1-defective triple-negative breast cancer (TNBC) cells. Mechanistically, PARPi generated cytoplasmic chromatin fragments with characteristics of micronuclei; these were found to activate cGAS/STING, downstream type I IFN signaling, and CCL5 secretion. Importantly, these effects were suppressed in PARPi-null TNBC cells, suggesting that this phenotype resulted from an on-target effect of PARPi on PARPi. PARPi also potentiated IFN-γ–induced PD-L1 expression in NSCLC cell lines and in fresh patient tumor cells; this effect was enhanced in ERCC1-deficient contexts. Our data provide a preclinical rationale for using PARPi as immunomodulatory agents in appropriately molecularly selected populations.

Introduction

Immune checkpoint inhibitors (ICIs) have revolutionized the prognosis of several aggressive cancers, notably non–small cell lung cancer (NSCLC). Recent impressive results of large phase III trials in NSCLC have reported unprecedented improvements in overall survival and progression-free survival when anti–programmed death receptor 1 or anti–programmed death ligand 1 (anti-PD-L1) was used in first-line therapy (1, 2). Likewise, remarkable 5-year survival rates of 16% have recently been reported in this disease (3), highlighting the ability of these agents to provide long-term tumor control. Although these results are encouraging, they also reinforce the fact that still only a minority of patients receive long-term benefit. Better understanding of the determinants of response to ICIs and identification of rational combinations that would increase the proportion of patients benefiting from these therapies are therefore crucial.

Several factors have been associated with response to immunotherapy: tumor-related factors (e.g., cancer cell mutations), microenvironment-related factors (e.g., expression of immune checkpoints, lymphocytic infiltration, or IFN signatures), and host-related factors (e.g., microbiome) (4). Defects in the DNA damage response (DDR) in cancer cells are key determinants of cancer immunogenicity. Indeed, DDR defects result in genomic instability and increased tumor mutational burden (TMB), which has been linked — at least in some cases — to better outcome upon ICI treatment (5). The best illustrations of this are probably mismatch repair-deficient tumors (6) and POLE/POLD1-mutated endometrial carcinoma and glioblastoma (7, 8), which are highly sensitive to ICIs, likely due to their increased neoantigen repertoire. High TMB has also been correlated with better response to ICIs in melanoma (9) and NSCLC (2, 10, 11). Other DNA repair defects, such as BRCA1/2 mutations, have been found to be enriched in ICI responders (12). However, a simple correlation among DNA repair defect–induced genomic instability, TMB, and response to ICIs cannot be claimed (5), as tumor heterogeneity (13) and other determinants of response also play a role that, importantly, seems to be independent from TMB in response to ICIs (14, 15).
Figure 1. Loss of ERCC1 results in increased type I IFN and cytokine signaling in NSCLC models in vitro. (A) Schematic of the generation of ERCC1-deficient clones from the parental NSCLC cell line A549. Full procedures are detailed in Friboulet et al. (31). (B) Western blot showing expression of ERCC1 in the parental (ERCC1WT/WT), heterozygous (ERCC1+/-), and ERCC1-knockout clones (c216, c295, and c375). (C) Heatmap displaying all significantly differentially expressed genes (significantly DEGs) in A549-ERCC1–/– cells compared with A549-ERCC1WT/WT cells, determined by RNA-Seq. n = 3; heatmap scale is a Z score. Threshold for differential expression was |LFC| > 1, and threshold for significance was FDR < 0.05. (D) GSEA of REACTOME pathways in A549-ERCC1–/– compared with A549-ERCC1WT/WT cells. Red, top 10 upregulated REACTOME pathways in A549-ERCC1–/– cells; yellow, top 10 downregulated REACTOME pathways in A549-ERCC1–/– cells. All pathways displayed had FDR < 0.05. AP folding*, antigen presentation folding assembly; Processing of capped intron*, processing of capped intron containing pre-mRNA; Interactions between a lymphoid cell and others*, interaction between a lymphoid cell and non-lymphoid cells. (E) GSEA of the REACTOME pathway “IFN-α/β signaling,” and associated heatmap showing the genes of the pathway, ranked by FDR. n = 3; heatmap scale is a Z score. In E and F, purple, significantly DEGs with FDR < 0.05 and |LFC| > 1; gray, nonsignificantly DEGs.

Another interface between DDR and immunogenicity that has recently generated particular attention in immuno-oncology is the cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway (16). This pathway, involved in the sensing of foreign or damaged cytosolic DNA, triggers innate immune responses through the activation of a signaling cascade connecting the cytoplasmic DNA sensor cGAS, several signal transducers including STING and TBK1, and eventually transcription factors (mainly IRF3 and NF-kB) that are collectively responsible for the induction of a type I IFN response (16). Thus, processes that disrupt nuclear DNA integrity and favor the translocation of DNA to the cytosol (either in the context of endogenous DNA repair deficiency or through the use of exogenous DNA-damaging agents) may activate cGAS/STING. For example, defects in homologous recombination (HR) genes (BRCA1,2 or FANCD2) and use of radiotherapy or S phase-dependent chemotherapies have been associated with cell cycle–dependent formation of cytoplasmic chromatin fragments (CCFs) and subsequent increase in STING signaling in breast cancer (17–20). Further, cGAS recently appeared to be an essential mediator of the antitumor effects of ICIs (21), and identification of cGAS/STING activators has become an area of intense research, with several ongoing phase I trials evaluating such molecules (22). As one of the main therapeutic challenges in immuno-oncology is currently to turn “cold,” non–T cell–inflamed tumors into “hot,” T cell–inflamed tumors, a better understanding of the cellular contexts in which targeted therapies can activate the cGAS/STING pathway is key.

DDR-deficient cancers that present elevated genomic instability may represent a favorable environment for selective cGAS/STING activation. Excision repair cross-complementation group 1 (ERCC1) deficiency is the most frequent DDR defect in NSCLC and occurs in 30%–50% of cases (23). The tumor suppressor protein BRCA1 is also frequently defective in triple-negative breast cancer (TNBC), following either germline mutation or somatic alteration (mutation or epigenetic silencing) (24, 25). Both ERCC1 and BRCA1 defects confer sensitivity to platinum-based therapy (26, 27) and PARP inhibitors (PARPi) (28, 29), and while PARPi have demonstrated their efficacy in advanced BRCA-deficient breast cancers (30), these agents are also being clinically assessed in ERCC1-defective (platinum-sensitive) NSCLC (PPIPSE trial, NCT02679963). Therefore, ERCC1 deficiency represents an attractive candidate for harnessing cGAS/STING activation in NSCLC, where ICIs have shown unprecedented efficacy, yet in only a small proportion of patients.

Here, we show that loss of ERCC1 in NSCLC leads to increased STING expression and constitutive activation of type I IFN signaling, which associates with enhanced T cell infiltration in patient-derived samples. Using a unique combination of isogenic models of ERCC1-deficient NSCLC, BRCA1-deficient and PARPi-resistant TNBC, we find that multiple clinical PARPi generate cytosolic DNA in a cell cycle– and DDR defect–dependent fashion, as a result of an on-target effect of PARPi. This in turn activates cGAS/STING signaling and elicits specific tumor cell–intrinsic immune responses, including type I IFN response and CCL5 secretion. PARPi further synergize with IFN-γ to induce cell surface PD-L1 expression in NSCLC models, a phenotype that is specifically enhanced in ERCC1-deficient cells. Our data reveal an unexpected immunomodulatory potential of PARPi that could be therapeutically exploited to enhance ICI efficacy in ERCC1-deficient NSCLC patients.

Results
ERCC1 deficiency in isogenic systems is associated with increased type I IFN signaling, cytokine signaling, and lymphocytic infiltration in NSCLC. We hypothesized that lack of function of a key DNA repair tumor suppressor gene, such as ERCC1, in tumor cells, might influence the molecular processes that control antitumor cell immune responses. To address this hypothesis in a relatively unbiased fashion, we first used RNA-Seq to profile the transcriptome of isogenic ERCC1-defective and WT A549 NSCLC cells (31, 32). Briefly, this isogenic model was generated using zinc finger targeting of ERCC1, and consists of one A549-ERCC1WT/WT parental cell line; one ERCC1-heterozygous cell line (herein referred to as A549-ERCC1+/-); and 3 ERCC1–/– clones, in which we reconfirmed no detectable levels of ERCC1 (Figure 1A, A and B) and which are characterized by exquisite sensitivity to cisplatin (31) — highlighting their clinical relevance (26) — and to PARPi (28) (Supplemental Figure 1A). Comparative transcriptomics of A549-ERCC1WT/WT and one ERCC1–/– clone (c216, referred to as A549-ERCC1–/– below) revealed 1486 significantly differentially expressed genes (DEGs; Figure 1C). Consistent with the known functions of the ERCC1/XPF endonuclease in the resolution of stalled replication fork and subsequent appropriate cell cycle progression, gene set enrichment analysis (GSEA) using the REACTOME pathway database revealed significant downregulation of several DNA repair–, cell cycle–, and DNA replication–related pathways in A549-ERCC1–/– cells (Figure 1D and Supplemental Figure 1B). This analysis also identified significant enrichment of numerous immune-related pathways in A549-ERCC1–/– cells — indeed, 24 immune-related pathways were found among the top 50 upregulated REACTOME terms (Supplemental Figure 1C) — suggesting a role for ERCC1 in modulating the immune characteristics of NSCLC cells in a cell-autonomous fashion. Among these pathways, the most significantly enriched were...
As ERCC1-deficient NSCLC tumors still harbor residual levels of ERCC1, we sought to investigate which threshold of ERCC1 deficiency was sufficient to induce such a type I IFN signature in vitro by using the ERCC1-heterozygous cell line of our isogenic model (A549-ERCC1+/– cell line). Interestingly, the type I IFN signature was also significantly enriched in this model, albeit to a lesser extent than in ERCC1–/– clones (NES = 1.86; FDR = 0.0131; Supplemental Figure 2, E and F). Whole exome sequencing of the isogenic clones did not identify mutations in any gene involved in immune signaling (28), suggesting the defect in ERCC1 as the most likely cause of the observed transcriptional dysregulation.

In other contexts, DDR defects have been linked to innate immune response and type I IFN signaling via cytosolic DNA sensing, notably involving the cGAS/STING pathway (16, 17). We hypothesized that loss of ERCC1 might modulate such signals. Although expression of STING, the major initiator of the cytosolic DNA–sensing pathway, was almost undetectable by Western blotting in A549-ERCC1WT/WT and A549-ERCC1+/– cells, we found elevated STING protein expression in A549-ERCC1–/– cells (Fig. 2A). Consistent with this, STING mRNA levels were increased more than 2.5-fold in A549-ERCC1–/– cells (log2 fold change [LFC] = 1.3769, FDR = 0.0009), compatible with a transcriptional mode of regulation. A similar upregulation of STING was also detected.

Figure 2. Loss of ERCC1 associates with increased STING expression in vitro and enhanced lymphocytic infiltration in human NSCLC samples. (A) Western blot illustrating ERCC1 and STING expression in A549-ERCC1WT/WT, A549-ERCC1+/–, A549-ERCC1–/– and A549-ERCC1–/– + isoform 202 isogenic cell lines. (B) Scatter box plots of ERCC1 protein expression (assessed by IHC staining) and the percentage of TILs (assessed through morphology) in a series of resected human NSCLC adenocarcinoma samples (n = 55). Tumors were classified according to the expression of ERCC1, and the corresponding level of TILs was plotted for each individual tumor. Mann-Whitney U test. (C) Representative images of ERCC1 and H&E stainings in 2 surgical specimens of resected lung adenocarcinoma. Case A shows low ERCC1 staining in tumor cells and high stromal TIL density; case B shows high ERCC1 staining in tumor cells and low stromal TIL density. Scale bars: 50 μm.
in the 2 other A549-ERCC1-deficient clones (Supplemental Figure 2G). In order to confirm that this observation was a primary effect of ERCC1 deficiency, we assessed STING expression in an isogenic cell line derived from the A549-ERCC1–/– clone in which the functional isoform of ERCC1 (isoform 202) had been stably reintroduced (herein referred to as “A549-ERCC1–/– + isoform 202”). Strikingly, reexpression of ERCC1 in this isogenic model led to loss of STING protein expression (Figure 2A), suggesting ERCC1-dependent reversible modulation of STING expression. Of note, cGAS expression was also increased in A549-ERCC1–/–
PARPi generate CCFs in a DNA repair defect- and cell cycle-dependent manner. (A) Schematic of the generation of BRCA1-revertant and PARPi-knockout cell lines from the parental BRCA1-mutant SUM149 TNBC cell line. (B) Representative immunofluorescence images of DMSO-, Ruca-, and Ola-exposed SUM149-BRCA1<sup>−/−</sup> and SUM149-PARP1<sup>−/−</sup> cells. Cells were exposed to 6 μM Ruca, 10 μM Ola, or DMSO (vehicle) during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bars: 20 μm. (C) Automated quantification of CCFs in SUM149-BRCA1<sup>−/−</sup>, SUM149-BRCA1<sup>−/−</sup>, and SUM149-PARP1<sup>−/−</sup> cells exposed to increasing doses of Ruca or Ola (μM). Shown is CCF number per cell normalized to DMSO. Mean ± SD, n = 3, Kruskal-Wallis test and post hoc Dunn’s test. (D) Western blot of histone H3 in the nuclear and cytoplasmic fractions of SUM149-BRCA1<sup>−/−</sup> and SUM149-PARP1<sup>−/−</sup> cells exposed to PARPi during 48 hours. β-Tubulin and lamin B1 were used as fraction purity controls. (E and F) Automated quantification of CCFs in A549-ERCC1<sup>WT/WT</sup> (E) and SUM149-BRCA1<sup>−/−</sup> (F) cells exposed to increasing doses of Ruca or Ola (μM) in the presence or absence of the cell cycle blocker CDKIIi RO-3306. Shown is CCF number per cell normalized to DMSO. Mean ± SD, n = 3, Kruskal-Wallis test and post hoc Dunn’s test, relative to DMSO control. *P < 0.05, **P < 0.01, ***P < 0.001.

In order to evaluate whether this enhanced cell-autonomous immune signaling could shape the tumor microenvironment, we estimated the extent of tumor-infiltrating lymphocytes (TILs) in a series of 55 human tumor samples derived from patients with resected lung adenocarcinoma (stages I, II, and IIIA). ERCC1 status in these tumors was evaluated by IHC as previously described (32), and TILs were assessed using a morphology-based coverage score. This analysis identified a statistically significant association between low ERCC1 expression and high levels of TILs (P = 0.0265, Mann-Whitney U test, Figure 2, B and C).

Taken together, these data suggest that ERCC1 loss results in a constitutive and cell-autonomous increase in STING expression and type I IFN signaling in NSCLC models in vitro. These observations are consistent with enhanced tumor lymphocytic infiltration in vivo in human NSCLC adenocarcinoma samples.

PARPi generate CCFs in an ERCC1 defect- and cell cycle-dependent manner. As previously reported (28), A549-ERCC1<sup>−/−</sup> cells show enhanced sensitivity to PARPi when compared with A549-ERCC1<sup>WT/WT</sup> cells, an effect that we confirmed in short-term survival assays (Figure 3A). We further hypothesized that PARPi—which not only inhibit the catalytic activity of PARPi, but also trap PARPi onto the DNA, causing stalled replication forks and subsequent double-strand breaks (DSBs) (34)—might specifically favor the formation of CCFs and in turn trigger cGAS/STING signaling in ERCC1-defective tumor cells.

To test this hypothesis, we exposed A549-ERCC1 isogenic cell lines to increasing concentrations of 2 different clinical PARPi, rucaparib and olaparib, and monitored the presence of CCFs using immunofluorescence. For each PARPi, we selected concentrations surrounding the SF50 (dose generating 50% cell survival in short-term assays, after 5 days of exposure to the drug) of the parental cell line; we therefore started with a dose corresponding to the SF80 of the WT cell line and applied a 2-fold increase at each subsequent dose to determine the final dose range. Although the number of CCFs in A549-ERCC1<sup>WT/WT</sup>, A549-ERCC1<sup>−/−</sup>, A549-ERCC1<sup>−/−</sup>, and A549-ERCC1<sup>−/−</sup> + isofrom 202 cells was not significantly different in the absence of PARPi (Supplemental Figure 3A), we observed a dose-dependent increase in CCF number upon PARPi exposure, an effect that was significantly enhanced in A549-ERCC1<sup>−/−</sup> and A549-ERCC1<sup>−/−</sup> isofrom 202 models compared with A549-ERCC1<sup>WT/WT</sup> cells (Figure 3, B and C; >6-fold difference at 10 μM olaparib, P = 0.0016; >4-fold difference at 5 μM olaparib, P = 0.03; 2-way ANOVA, post hoc Šidák’s test), but not in A549-ERCC1<sup>−/−</sup> + isofrom 202 cells. These findings were further validated in the independent H1975-ERCC1 isogenic NSCLC model; in these cells, ERCC1 loss caused increased CCF levels in the absence of treatment (Supplemental Figure 3A; 2.5-fold increase, P = 0.0035, Welch’s t test), a phenotype that was enhanced upon PARPi exposure (Supplemental Figure 3, B and C).

BRCA1-defective tumor cells are also profoundly sensitive to PARPi (29). We therefore assessed whether the effects seen in ERCC1-defective cells could be reproduced in BRCA1-defective cells. To do this, we used recently described isogenic series derived from the BRCA1-mutant TNBC SUM149 cell line (35, 36). This isogenic series consists of 3 cell lines (Figure 4A): one BRCA1-mutant parental line (SUM149-BRCA1<sup>−/−</sup>); one BRCA1-mutant reverted line that is PARPi-resistant following restoration of the native BRCA1 reading frame and functionality (35) (SUM149-BRCA1<sup>−/−</sup>); and one SUM149 clone with PARPi resistance caused by loss of PARPi (36) (SUM149-PARP1<sup>−/−</sup>). In the absence of PARPi, SUM149-BRCA1<sup>−/−</sup> cells showed a significantly higher number of CCFs compared with SUM149-BRCA1<sup>−/−</sup> cells (>8-fold increase, P = 0.0233, Welch’s t test; Supplemental Figure 3A). Upon PARPi exposure, we observed a dose-dependent increase in CCF number in SUM149-BRCA1<sup>−/−</sup> cells, but not in SUM149-PARP1<sup>−/−</sup> cells, confirming the on-target effect of PARPi in triggering this phenotype (Figure 4, B and C); SUM149-BRCA1<sup>−/−</sup> cells showed an intermediate phenotype (Figure 4C), confirming that the generation of CCFs was a BRCA1-dependent process. As PARPi have been reported to modulate histone PARylation and chromatin structure (37), thereby potentially promoting transcription of retroelements, we further confirmed the presence of chromatin (i.e., histone-bound DNA as opposed to naked DNA) by assessing the presence of histone H3 in cytoplasmic fractions. This demonstrated increased H3 levels after PARPi exposure in SUM149-BRCA1<sup>−/−</sup> cells, but not in SUM149-PARP1<sup>−/−</sup> cells, thus confirming, respectively, the presence of cytoplasmic chromatin and the on-target effect of PARPi (Figure 4D). Consistent with this finding, assessment of H3K27me3 by immunofluorescence in the A549-ERCC1 isogenic cells revealed colocalization of this heterochromatin marker with CCFs in PARPi-exposed cells (Supplemental Figure 3D).

As PARPi cause S phase–dependent DNA damage, we hypothesized that the observed CCFs might, at least in part, be micronuclei (19, 20). Micronuclei are signs of genomic or chromosomal instability which have two main characteristics: their formation is cell cycle dependent, as they arise during anaphase from lagging chromosomes or chromatid bridges following unresolved DNA lesions; and they contain heterochro-
Figure 5. PARPi-induced CCFs are detected by cGAS. (A) Representative immunofluorescence images of DMSO-, Ruca-, and Ola-exposed A549-ERCC1WT/WT and A549-ERCC1–/– cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bars: 20 μm. Images corresponding to the DMSO condition originate from the same image field as those shown in Figure 3B. (B) Automated quantification of cytoplasmic cGAS foci in A549-ERCC1 isogenic cells exposed to increasing doses of Ruca or Ola (μM). Shown are numbers of cytoplasmic cGAS foci per cell normalized to DMSO. Mean ± SD, n = 3, Kruskal-Wallis test and post hoc Dunn’s test, relative to DMSO control. Results shown are representative of 2 experiments performed with similar results. (C) Representative immunofluorescence images of DMSO-, Ruca-, and Ola-exposed SUM149-BRCA1mut, SUM149-BRCA1rev, and SUM149-PARP1–/– cells. Cells were exposed to 6 μM Ruca, 10 μM Ola, or DMSO (vehicle) during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bars: 20 μm. (D) Automated quantification of cytoplasmic cGAS foci in SUM149-BRCA1mut, SUM149-BRCA1rev, and SUM149-PARP1–/– cells exposed to increasing doses of Ruca or Ola (μM). Shown are numbers of cytoplasmic cGAS foci per cell normalized to DMSO. Mean ± SD, n = 3, Kruskal-Wallis test and post hoc Dunn’s test, relative to DMSO control. Results shown are representative of 2 experiments performed with similar results. (E) Scatter box plots displaying cGAS foci intensity for each colocalizing CCF foci in A549-ERCC1WT/WT and A549-ERCC1–/– cells exposed to DMSO (vehicle), 15 μM Ruca, or 40 μM Ola. n = 3, Kruskal-Wallis test and post hoc Dunn’s test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Figure 6. cGAS-mediated detection of PARPi-induced CCFs activates STING signaling in an ERCC1-dependent manner. (A and B) Western blot of pTBK1 in A549-ERCC1WT/WT and A549-ERCC1–/– cells (A) or H1975-ERCC1WT/WT and H1975-ERCC1–/– cells (B) upon PARPi exposure. Cells were exposed for 48 hours to DMSO (vehicle) and a range of doses of Ola (μM). Lysates were probed with the indicated antibodies. (C) Western blot of pTBK1 in DMSO- or Ruca-treated H1975-ERCC1WT/WT cells in the context of siRNA silencing of cGAS/STING. Cells were transfected with RNAiMAX (Thermo Fisher Scientific), siCTRL, siSTING, siGAS, or siGAS + siSTING and exposed to DMSO (vehicle) or 25 μM Ruca, and lysates were probed with the indicated antibodies. (D) Western blot of pTBK1 in DMSO- or Ola-treated H1975-ERCC1WT/WT cells upon cell cycle blockade. Cells were exposed to DMSO or 20 μM or 80 μM Ola in the presence or absence of the cell cycle blocker CDK1i RO-3306. Lysates were probed with the indicated antibodies. Graph: pTBK1/TBK1 relative intensity (%DMO) was measured for each condition and normalized to DMSO. Mean ± SD, n = 3; **P < 0.05, Kruskal-Wallis test and post hoc Dunn’s test, relative to DMSO control.
PARPi-induced CCFs activate cGAS/STING signaling in ERCC1-deficient NSCLC cells. To investigate the potential of PARPi-induced CCFs to activate cGAS/STING signaling, we assessed the ability of cGAS to form foci through relocation to CCFs. Immunofluorescence staining of cGAS in A549-ERCC1 isogenic cell lines exposed to increasing concentrations ofrucaparib or olaparib revealed a significant dose-dependent increase in the number of cytoplasmic cGAS foci in A549-ERCC1–/– and A549-ERCC1–/– cells, but not in A549-ERCC1WT/WT cells (Figure 5, A and B; P = 0.0122, P = 0.0123, and P = 0.1657, respectively; Kruskal-Wallis test). Similar results were obtained in the independent H1975-ERCC1 isogenic NSCLC model (Supplemental Figure 4, A and B). Increased formation of cytoplasmic cGAS foci was also detected in SUM149-BRCA1mut cells after PARPi exposure, at a higher level than in SUM149-BRCA1wt cells (1.4-fold difference at 20 μM olaparib, P = 0.0033, 2-way ANOVA, post hoc Šidák’s test) (Figure 5, C and D). More importantly, no increase in cytoplasmic cGAS foci was detected in the PARPi-resistant SUM149-PARPi1–/– cell line, supporting that the minimal levels of CCFs measured in this cell line did not trigger cGAS relocalization. Analysis of cGAS staining intensity within CCFs revealed a significant increase in cGAS foci/CCF colocalization upon PARPi exposure in both NSCLC ERCC1 isogenic models (Figure 5E and Supplemental Figure 4C; P < 0.0001, Kruskal-Wallis test), thus confirming that cGAS relocalized to CCFs following PARPi exposure.

We then investigated whether the detection of CCFs by cGAS could activate STING signaling. Analysis of phosphorylated TBK1 (pTBK1, a key downstream effector of STING signaling) revealed a dose-dependent increase upon PARPi exposure in A549-ERCC1–/– and A549-ERCC1–/– models, but not A549-ERCC1WT/WT cells (Figure 6A and Supplemental Figure 4D). Consistent results were observed in the H1975-ERCC1 isogenic model, where an increase in pTBK1 was detected upon PARPi exposure, which was more pronounced in the H1975-ERCC1–/– cells (Figure 6B and Supplemental Figure 4E). This suggested the ERCC1 dependence of PARPi-induced TBK1 phosphorylation. Furthermore, while silencing of either cGAS or STING only moderately decreased PARPi-induced TBK1 phosphorylation in A549-ERCC1–/– cells (Supplemental Figure 4F), simultaneous silencing of both sensors allowed complete abrogation of pTBK1, as observed in H1975-ERCC1WT/WT cells (Figure 6C). We then evaluated pTBK1 in the SUM149-BRCA1 isogenic TNBC model. Consistent with results obtained in the NSCLC models, we found a dose-dependent increase in pTBK1 upon PARPi exposure in SUM149-BRCA1mut but not SUM149-BRCA1wt cells (Supplemental Figure 4G).

Because CCFs can also be detected by alternative STING-independent pattern recognition receptors (PRRs), namely the Toll-like receptor (TLR) and RIG-1-like receptor (RLR) pathways, we monitored the activation of those pathways after PARPi exposure. No activation of the TLR or RLR effectors could be detected upon PARPi exposure (Supplemental Figure 4, H and I), suggesting that the detection of CCFs following PARPi inhibition is relatively specific to the cGAS/STING pathway.

Because our previous observations showed cell cycle dependence of CCF formation (Figure 4, E and F), we monitored TBK1 phosphorylation upon cell cycle blockade by CDK1i. Although CDK1i itself appeared to increase baseline pTBK1, we could detect an abrogation of the previously observed increase in TBK1 phosphorylation upon PARPi exposure (Figure 6D). Collectively, these results support the notion that PARPi-induced CCFs activate cGAS/STING signaling and that this effect relies on the presence of specific DNA repair defects.

PARPi promote secretion of CCL5 and activate type I IFN signaling. Increased production of the chemotactic chemokine CCL5 has been previously reported in the context of DDR deficiency and following treatment with S phase–dependent DNA-damaging agents or ionizing radiation (17, 19, 20). We therefore hypothesized that PARPi might enhance CCL5 production, especially in ERCC1-deficient cells. Quantitative RT-PCR (RT-qPCR) analyses of CCL5 mRNAs revealed dose-dependent activation of CCL5 transcription in both A549-ERCC1–/– and A549-ERCC1WT/WT cells following PARPi exposure (Figure 7A), while baseline expression levels were 12-fold higher in A549-ERCC1–/– cells compared with A549-ERCC1WT/WT cells (Figure 7B). Consistent with these observations, quantification of CCL5 protein concentration in cell supernatants using ELISA revealed a similar dose-dependent increase in CCL5 secretion upon PARPi exposure in A549-ERCC1–/– but not A549-ERCC1WT/WT, A549-ERCC1–/– or A549-ERCC1–/– isoform 202 cells (Figure 7C). Depletion of STING and cGAS by siRNA resulted in a suppression of CCL5 transcription and secretion, suggesting the involvement of cGAS/STING in this process (Figure 7, A–C). Similarly, SUM149-BRCA1mut cells, but not SUM149-BRCA1wt cells, displayed enhanced expres-
Figure 8. ERCC1 deficiency and PARPi exposure potentiate IFN-γ–induced cell-surface PD-L1 expression. (A) Quantification of PD-L1 cell surface expression by flow cytometry in H1975-ERCC1WT/WT and A549-ERCC1WT/WT cells upon PARPi and IFN-γ exposure. Cells were treated for 48 hours with DMSO, 15 μM Ruca, 3 μM Talazo, or/and 500 U/ml IFN-γ. MFI ± SD normalized to IFN-γ; n = 4, 2-way ANOVA and post hoc Tukey’s test. (B) Corresponding flow cytometry histograms; shown is the percentage of PD-L1–positive cells. (C) Quantification of PD-L1 cell surface expression by flow cytometry in A549-ERCC1WT/WT and A549-ERCC1–/– cells treated for 48 hours with DMSO, 3 μM Talazo, and/or 500 U/ml IFN-γ. MFI ± SD, 2-way ANOVA and post hoc Tukey’s test. (D) RT-qPCR analysis of RNA isolated from A549-ERCC1WT/WT and A549-ERCC1–/– cells exposed to PARPi and/or IFN-γ. Cells were treated for 48 hours with DMSO, 3 μM Talazo, or 13.5 μM Ruca, and/or 500 U/ml IFN-γ. PD-L1 mRNAs were analyzed relative to GAPDH (to control for cDNA quantity). Shown are arbitrary units of gene expression, normalized to A549-ERCC1WT/WT DMSO-treated control. Mean ± SD, n = 3, 2-way ANOVA and post hoc Tukey’s test. (E) Quantification of PD-L1 cell surface expression by flow cytometry in SUM149-PARP1mut and SUM149-PARP1–/– cells treated for 48 hours with DMSO, 3 μM Talazo, and/or 500 U/ml IFN-γ. MFI ± SD, n = 3, 2-way ANOVA and post hoc Tukey’s test. Corresponding flow cytometry histograms are shown at the bottom. *P < 0.05, **P < 0.01, ***P < 0.001.
RATIONALLY activate, in a cell-autonomous fashion in NSCLC cells, a type I IFN immune response that is enhanced in the context of ERCC1 deficiency, and can be linked to the secretion of CCL5 in our models.

PARPi synergize with IFN-γ to induce cell-surface PD-L1 expression. PD-L1 is a major immune checkpoint protein expressed by tumor cells to evade immunosurveillance. PD-L1 induction is classically triggered by IFN-γ, which mediates the activation of type II IFN signaling cascade (38), but recent data suggest that platinum-based chemotherapies (39) as well as some PARPi (40) can also transiently enhance PD-L1 expression. Although the mechanisms underlying these effects are largely unknown, activation of PD-L1 expression following S phase–specific DNA damage has been associated with cGAS/STING recruitment (17). Because our previous data mostly pointed toward stimulation of type I IFN signaling through cGAS/STING in response to PARPi, we questioned whether PARPi could synergize with IFN-γ to induce PD-L1 expression and whether ERCC1 status would influence this modulation. We exposed A549-ERCC1 isogenic and H1975-ERCC1 isogenic cell lines to PARPi and/or IFN-γ, and monitored cell-surface PD-L1 expression. Consistent with the published literature (40), we observed a significant dose-dependent upregulation of PD-L1 expression after treatment with rucaparib, talazoparib, or niraparib as monotherapy in both models (Figure 8, A and B).

We next evaluated whether the production of other major chemokines was upregulated by PARPi exposure. Although a significant increase in IFNBI transcription was observed in SUM149-BRCA1mut cells exposed to olaparib (Supplemental Figure 5C), no increase in the corresponding secreted protein could be detected in cell supernatants (Supplemental Figure 5D). Similarly, no secretion of IFN-γ or TNF-α was detected after olaparib exposure in this cell line (Supplemental Figure 5E).

To comprehensively characterize cell-autonomous immunomodulation induced by PARPi, we performed RNA-Seq on A549-ERCC1WT/WT and A549-ERCC1–/– cells exposed to talazoparib, the most potent and specific clinical PARPi. This demonstrated significant upregulation of a number of genes involved in type I IFN signaling (Figure 7, D and E), which was associated with a significant enrichment of the type I IFN signature in A549-ERCC1–/– cells (NES = 2.12; FDR = 0.0018). Although this upregulation was observed in both A549-ERCC1–/– and A549-ERCC1WT/WT cells, the corresponding enrichment was more modest in WT A549 cells (NES = 1.64; FDR = 0.0314), highlighting the role of ERCC1 deficiency in potentiating this phenotype. These data support the hypothesis that PARPi specifically activate, in a cell-autonomous fashion in NSCLC cells, a type I IFN immune response that is enhanced in the context of ERCC1 deficiency, and can be linked to the secretion of CCL5 in our models.

PARPi synergize with IFN-γ to induce cell-surface PD-L1 expression. PD-L1 is a major immune checkpoint protein expressed by tumor cells to evade immunosurveillance. PD-L1 induction is classically triggered by IFN-γ, which mediates the activation of type II IFN signaling cascade (38), but recent data suggest that platinum-based chemotherapies (39) as well as some PARPi (40) can also transiently enhance PD-L1 expression. Although the mechanisms underlying these effects are largely unknown, activation of PD-L1 expression following S phase–specific DNA damage has been associated with cGAS/STING recruitment (17). Because our previous data mostly pointed toward stimulation of type I IFN signaling through cGAS/STING in response to PARPi, we questioned whether PARPi could synergize with IFN-γ to induce PD-L1 expression and whether ERCC1 status would influence this modulation. We exposed A549-ERCC1 isogenic and H1975-ERCC1 isogenic cell lines to PARPi and/or IFN-γ, and monitored cell-surface PD-L1 expression. Consistent with the published literature (40), we observed a significant dose-dependent upregulation of PD-L1 expression after treatment with rucaparib, talazoparib, or niraparib as monotherapy in both models (Figure 8, A and B, and 9A).
el: although a significant synergy between talazoparib and IFN-γ could be observed in parental SUM149-BRCA1mut cells, this effect was completely abrogated in SUM149-PARP1–/– cells, where only IFN-γ could induce cell-surface PD-L1 (Figure 8E). To explore this interaction between PARPi and type II IFN signaling, we assessed whether PARPi could modulate the activation of STAT1, a key protein in the IFN-γ signaling pathway that mediates PD-L1 induction. Although exposure to PARPi monotherapy did not induce STAT1 phosphorylation, enhanced STAT1 phosphorylation was detected following combination treatment of PARPi plus IFN-γ, compared with IFN-γ alone (Supplemental Figure 6C). Interestingly, this effect was abrogated upon cell cycle blockade with the CDK1i RO-3306, suggesting that progression through the cell cycle is required for the potentiation of STAT signaling by PARPi.

Supplemental Figure 6A). Interestingly, cotreatment with PARPi plus IFN-γ was synergistic and could potentiate the induction of PD-L1 expression (Figure 8, A and B). This induction was more profound in A549-ERCC1WT/WT and H1975-ERCC1WT/WT models when compared with their ERCC1-proficient counterparts, at both the cell surface and transcriptional levels (Figure 8, C and D). To assess the specificity of the observed effect, we evaluated the membrane expression of TLR4, an immune-related cell surface marker that has been described to be positively correlated with PD-L1 expression in NSCLC samples (41). No TLR4 induction could be detected under similar conditions, suggesting that PD-L1 expression is induced at the cell surface.

Figure 10. Model of ERCC1 defect-dependent activation of cGAS/STING following PARPi exposure. (i) ERCC1WT/WT cells have a functional DDR and adequately maintain genome integrity. (ii) Upon PARPi exposure, exogenous DNA damage is triggered, mostly initiated by PARP1 itself trapped onto the DNA at sites of spontaneous single-strand breaks (SSBs). (iii) During the S phase of the cell cycle, trapped PARP1 generates lesions that prevent the progression of replication forks, leading to fork stalling and subsequent formation of DSBs. (iv) In ERCC1WT/WT cells, most trapped PARP1 lesions are removed, which enables the processing of DSBs through HR and eventually allows replication to restart. Residual inadequately repaired lesions cause moderate formation of CCFs. (v) The low levels of CCFs generated are unable to trigger the pTBK1/IRF3/NF-κB signaling cascade or subsequent transcription of type I IFN genes; PD-L1 is moderately induced. (vi) ERCC1–/– cells are exposed to increased endogenous DNA damage following the loss of ERCC1. This generates minimal levels of CCFs. (vii) Upon PARPi exposure, ERCC1–/– cells are subjected to an additional exogenous source of DNA damage. (viii) During the S phase of the cell cycle, trapped PARP1 generates lesions that prevent the progression of replication forks, leading to stalling of forks and subsequent formation of DSBs. In the absence of ERCC1, trapped PARP1 lesions cannot be adequately resolved, which triggers increased DSBs and eventually generates high levels of CCFs. (ix) CCFs are detected by cGAS and, due to the enhanced expression of STING in ERCC1–/– cells, these efficiently activate cGAS/STING signaling. Activated STING homodimer phosphorylates TBK1, which in turn phosphorylates IRF3 and NF-κB; this triggers their translocation into the nucleus and results in the transcription of type I IFN genes: CCL5 and other type I IFN cytokines are secreted. Higher PD-L1 expression is induced at the cell surface.
We next sought to assess whether these mechanisms would also operate in patients and exposed fresh cells from a patient’s NSCLC pleural effusion sample to PARPi and IFN-γ. After selection of epithelial cell adhesion molecule-positive (EpCAM⁺) cells, we quantified PD-L1 cell-surface expression by flow cytometry. This revealed a similar PD-L1 induction upon PARPi exposure, which was again potentiated by IFN-γ, consistent with our in vitro findings (Figure 9A).

As PARPi have a dual mechanism of action (i.e., inhibition of the PARylation catalytic activity of PARP1 and PARP1 trapping), we also sought to evaluate whether PARylation levels or PARPi expression would correlate with PD-L1 expression in human tumor samples. We performed immunostaining of PAR, PARP1, and PD-L1 in a series of 49 resected stage I/II NSCLC samples. No correlation between PARPi expression and PD-L1 staining (Supplemental Figure 6, E and F) was found. A significant inverse correlation was found between PAR and PD-L1 levels on tumor cells (mean PARylation H-score of 100 in PD-L1-low vs. 60 in PD-L1-high tumor cells; P = 0.003; Mann-Whitney U test; Figure 9, B and C) but not PD-L1 expression on immune cells (Supplemental Figure 6D), consistent with a previous report in breast cancer specimens (40).

A proposed model to explain cGAS/STING activation following PARPi exposure in tumor cells with ERCC1 deficiency. Although several scenarios may explain our findings, we propose the following model, which is consistent with our observations (Figure 10): ERCC1WT/WT cells adequately repair endogenous DNA lesions. PARPi exposure causes DNA damage, mostly initiated by PARPi itself trapped onto the DNA at sites of spontaneous single-strand breaks. Trapped PARPi generates stalled replication forks and subsequent DSBs during DNA replication. In ERCC1WT/WT cells, trapped PARPi lesions can be adequately excised, a process in which ERCC1 is thought to play a major role (28). Following excision, repair of DSBs occurs through HR, and replication restarts. Residual unrepaired lesions cause minimal formation of CCFs, which are insufficient to trigger cGAS/STING signaling (Figure 10, i–iv). By contrast, ERCC1⁻/⁻ cells are exposed to increased levels of endogenous DNA damage, which are further enhanced upon PARPi exposure. Trapped-PARPi lesions cannot be appropriately resolved in the absence of ERCC1 (28), which prevents the subsequent processing of DSBs through HR (Figure 10, v–vii). This results in the accumulation of stalled replication forks, subsequent DSBs, and unrepaired DNA lesions, which eventually cause increased micronuclei formation and CCF generation (Figure 10, vii). These are detected by cGAS, which activates the STING/pTBK1 cascade and results in the transcription of type I IFN genes, including CCL5 (Figure 10, viii).

Discussion

DNA repair deficiency is a hallmark of cancer that has been therapeutically exploited for more than 50 years using DNA-damaging cytotoxic chemotherapies and more recently, with the advent of targeted DNA repair inhibitors such as PARPi, using synthetic lethality. Here, we show that multiple clinical PARPi can trigger the activation of innate immune pathways in a cell-autonomous fashion in vitro. By studying multiple isogenic models of DDR deficiency or PARPi resistance, and using fresh and archived tumor samples, we found that PARPi can elicit a cGAS/STING/pTBK1/pIRF3/type I IFN response in cancer cells. Importantly, this response was exacerbated in ERCCI-deficient NSCLC contexts. We further showed that ERCCI deficiency and PARPi were synergistic with IFN-γ in inducing PD-L1 expression (Figures 8 and 9), thereby providing a rationale for strategies combining PARPi and anti–PD-(L)1 therapies in appropriately molecularly selected populations.

Despite significant improvements in outcome brought by the advent of anti–PD-(L)1 therapies, NSCLC still represents the leading cause of cancer-related death. Only a minority of patients currently benefit from ICI, and strategies to turn “cold” tumors into “hot” tumors are being actively investigated. Interestingly, high TIL levels correlate with improved survival following neoadjuvant therapy in TNBC (42) — an observation that was also made in some NSCLC series in the adjuvant setting (43). In line with our findings, preclinical data evaluating rucaparib in combination with anti–PD-(L)1 in syngeneic models of ovarian cancer have suggested a possible role for PARPi in promoting tumor lymphocytic infiltration, and increased benefit compared with anti–PD-(L)1 monotherapies in BRCA1-mutated tumors (44). Our observation that PARPi trigger cGAS/STING signaling (Figures 5 and 6) and favor secretion of lymphoattractant chemokines such as CCL5 in ERCCI-deficient NSCLC (Figure 7) suggests that PARPi could be used as immunomodulatory agents to trigger lymphocytic infiltration in this histotype. Conversely, adding anti–PD-(L)1 therapies to PARPi might overcome the immune escape mechanisms resulting from PARPi-induced PD-L1 upregulation on tumor cells. Importantly, recent data from the large randomized double-blind phase III study Keynote 189 (NCT02578680) evaluating the combination of pembrolizumab and platinum-based chemotherapy in first-line metastatic NSCLC have reported impressive benefits in progression-free and overall survival (HR for death = 0.49; 95% CI, 0.38–0.64; P < 0.001) (1). These results changed practice, setting up the framework for recommending anti–PD-(L)1 therapy in combination with platinum-based doublet chemotherapy in first-line advanced NSCLC. Interestingly and contrary to previous studies evaluating anti–PD-(L)1 monotherapy, this benefit was observed across all subgroups and was independent of baseline PD-L1 tumor expression score, suggesting that other tumor characteristics — such as DDR status — might play a role in response to this combination. Platinum sensitivity is a relevant phenotypical biomarker of sensitivity to PARPi (27), which suggests that PARPi — which are much better tolerated and do not cause severe bone marrow toxicity — might represent an interesting alternative or complement (in the maintenance setting) to platinum-based chemotherapy in combination with anti–PD-(L)1 agents in NSCLC. The development of clinical trials addressing this question is underway.

TMB is an important determinant of response to ICI (9, 10). While various DDR defects have been shown to critically contribute to the accumulation of mutations in the tumor genome, only some of them have proven their predictive value as biomarkers of response to anti–PD-(L)1 therapy (6, 45). ERCCI deficiency has been associated with increased mutation frequency and genomic instability in mice (46), an observation that is consistent with the known roles of ERCCI in processes that ensure chromosomal stability and maintenance of genome
integrity, such as the interstrand crosslink DNA repair pathway (47) and resolution of Holliday junctions (48). However, no formal studies have yet been conducted to assess whether ERCC1 status might influence TMB in NSCLC. This would be best addressed by interrogating large datasets (e.g., The Cancer Genome Atlas [TCGA]) for an inverse correlation between ERCC1 isoform 202 expression and TMB. Furthermore, whether ERCC1 status itself represents an independent predictive biomarker of response to anti–PD-(L)1 in NSCLC is currently unknown and deserves further investigation.

Although our study focused on ERCCI — the most frequent DDR deficiency in NSCLC — we can hypothesize that our findings may be applicable to other DDR defects detected at a lower frequency in NSCLC. For example, BRCA1, BRCA2, ATM, and MSH2 (mutated in 5%, 6%, 9%, and 3% of NSCLC cases, respectively; ref. 49) have also been associated with PARPi sensitivity and type I IFN signature (50–53). Interestingly, Teo et al. recently reported that somatic DDR alterations that were associated with improved clinical outcomes in platinum-treated patients with advanced urothelial carcinoma (54) also correlated with longer progression-free survival and overall survival upon anti–PD-(L)1 therapy (15). The authors reported that 25% of patients presented tumors with alterations in DDR genes, the most commonly altered genes being ATM, POLE, BRCA2, ERCC2, FANCA, and MSH6. Overall, these observations suggest that the interplay among DDR deficiency, platinum or PARPi sensitivity, and anticancer immune response operates in several tumor types and can influence multiple DDR defects.

cGAS is a potent sensor of almost any form of cytoplasmic DNA. It can detect free DNA, arising from reverse transcription of endogenous retroviruses (55) or mitochondrial DNA instability (56); and micronuclei, which arise from genomic instability and display chromatin-like structures, sometimes surrounded by a fragile lamin B1 membrane (19). Our data provide evidence that clinical PARPi can induce cytosolic DNA (Figures 3 and 4), which is at least in part in the form of micronuclei, and subsequently activates cGAS/STING signaling (Figures 5 and 6). In particular, our observation that these effects are abrogated in PARPi-null cells supports a direct on-target effect of these drugs, which is mostly mediated by their PARP-trapping potential (36). Furthermore, use of several specific isogenic models demonstrated that this effect is enhanced in several DNA repair-deficient contexts, notably ERCC1 and BRCA1 deficiency. This extends and is consistent with previous publications that reported activation of cGAS/STING by micronuclei following either ionizing radiation (19, 20) or S phase–specific chemotherapies (17, 18), and published data that showed PARPi-mediated induction of IFN signals (notably increased STAT1 phosphorylation) in BRCA1-deficient contexts (20). Importantly, our observation that the immune phenotype of the ERCCI-heterozygous model closely resembles that of the ERCCI−/− clones suggests that our findings may be clinically relevant for NSCLC, where some residual expression of ERCCI is usually retained.

In conclusion, we provide a scientific rationale for assessing PARPi in combination with anti–PD-(L)1 therapy in molecularly selected DNA repair-deficient populations. While several clinical trials are currently combining PARPi with anti–PD-(L)1 in BRCA1/2-mutant breast or ovarian cancers, other histologies, such as NSCLC in which anti–PD-(L)1 therapies have already shown impressive results, might also benefit from such association. Basket clinical trials are planned to be launched soon to explore this question.

Methods

Additional methods are described in Supplemental Methods.

Study design. The aim of this study was to assess the immunomodulatory potential of PARPi, their ability to trigger specific cancer cell–associated immune responses, and their potential to enhance cancer cell immunogenicity through cell-autonomous mechanisms. Our prespecified hypothesis was that PARPi might have intrinsic immunomodulatory properties capable of activating immune signaling in a cell-autonomous fashion in cancer cells, specifically in those harboring DDR defects. Hence, we used a combination of in vitro isogenic systems of DDR-deficient and PARPi-sensitive or -resistant NSCLC and TNBC. All laboratory experiments were performed in at least 3 independent biological replicates to allow appropriate statistical calculations, using multiple well-characterized models and several PARPi evaluated in dose response experiments at clinically relevant concentrations. RNA-Seq was performed to generate at least 20 million reads per sample. For each condition, 3 biological replicates were included in the RNA-Seq analysis. Clinically relevant findings were further assessed in retrospectively analyzed archived patient tumor samples as well as one fresh prospectively collected pleural effusion.

Cell lines. SUM149, A549, and H1975 cells were obtained from ATCC. The generation of SUM149-BRCA1−/− and SUM149-PARP1−/− secondary mutant cell lines was performed using CRISPR/Cas9 site-directed mutagenesis, as previously described (35, 36). The secondary mutant cell lines A549-ERCC1−/− and H1975-ERCC1−/− were generated using zinc finger nuclease gene targeting, as described previously (31). SUM149 cells were cultured in Ham’s F12 nutrient mixture with 10% FBS, 1 µg/ml insulin, and 500 ng/ml hydrocortisone. A549 and H1975 cells were cultured, respectively, with high-glucose DMEM and RPMI 1640 medium with 10% FBS. The cells were cultured under physiological conditions at 37°C and 5% CO2. All cell lines were short tandem repeat (STR) typed using StemElite ID (Promega) to confirm identity prior to the study, and verified for mycoplasma contamination every 2 months using MycoAlert (Lonza).

Drugs and chemicals. The PARPi olaparib (AZD-2281, Astra Zeneca), rucaparib (PF-01367338, Clovis Oncology), and talazoparib (BMN-673, Pfizer) were purchased from Selleck Chemicals. Niraparib (MK-4827, Tesaro) was obtained from MedChemExpress. Inhibitor stock solutions were prepared in DMSO and stored in aliquots at −80°C. Hydroxyurea (HU), 5-fluorouracil (5-FU), and the CDK1 inhibitor RO-80–80°C. Hydroxyurea (HU), 5-fluorouracil (5-FU), and the CDK1 inhibitor RO-3306 were obtained from Sigma-Aldrich. IFN-γ–1b (IMUKIN) was purchased from Boehringer.

Immunofluorescence and image analysis. Immunofluorescence assays were performed in 96-well plates. Cells were fixed in 4% paraformaldehyde (PFA) in PBS during 20 minutes at room temperature (RT), washed twice with PBS, and permeabilized with 0.5% Triton X-100 in PBS for 10 minutes. After 2 additional washes, cells were blocked with 2% BSA, 2% FBS in PBS (IFF) for 1 hour at RT. Cells were then incubated with primary antibodies in IFF at 4°C overnight.
The cells were then washed 3 times with PBS, each for 10 minutes, followed by incubation with Alexa Fluor 594-conjugated rabbit and Alexa Fluor 647-conjugated mouse secondary antibodies (Thermo Fisher Scientific), 1 μg/ml DAPI, and 1:400 PicoGreen (Thermo Fisher Scientific) in IFF for 1 hour at RT. After that, cells were washed again 3 times with PBS, and 100 μl PBS was finally added to each well prior to imaging. Plates were imaged using an Operetta high-content imaging system (PerkinElmer). Quantification of the number of CCFs, micronuclei, and cGAS foci was performed under identical microscopy settings between samples, using the Columbus image analysis system (PerkinElmer). Twenty-five randomly selected fields containing more than 200 cells were analyzed within 3 individual replicates for each sample.

Detection of secreted cytokines. Detection of secreted cytokines in cell supernatants was performed through ELISA detection. Culture media were collected after a 72-hour culture, and cell numbers were counted for normalization. The media were dispensed in 96-well V-bottomed plates and centrifuged at 500 g for 5 minutes to pellet cells and debris. The resulting supernatants were used for ELISA detection with the following kits: Human CCL5 ELISA MAX Deluxe kit (catalog 440806), Human IFN-γ ELISA MAX Standard kit (catalog 430103), and Human TNF-α ELISA MAX Deluxe kit (catalog 430206) from BioLegend; and Human IFN-β ELISA kit (catalog 41410-1) from PBL Assay Science. Assays were performed in 4 replicates following the manufacturers’ protocols. Absorbance was evaluated using a VICTOR multilabel plate reader (PerkinElmer).

Flow cytometry analyses. Cells were detached using Versene solution (Thermo Fisher Scientific) and transferred to round-bottom FACS tubes. After 5 minutes of centrifugation at 500 g, the cells were washed with PBS and incubated at 4°C for 30 minutes with primary antibodies, diluted in 5% BSA in PBS. The supernatants were removed after centrifugation, and the cells were washed again twice with PBS. The pellets were finally diluted in 250 μl PBS containing 1 μg/ml propidium iodide (PI) prior to analysis. Cell-surface expression of PD-L1 and TLR-4 was quantified and analyzed by flow cytometry on an LSR II flow cytometer (BD Biosciences). PI was used as a viability marker. Data analysis was performed using the FlowJo software package.

Statistics. No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. All bar graphs show mean values with error bars (SD); 95% confidence intervals were used, and significance was considered when P was less than 0.05; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Study approval. No specific approval was required for this study, as no experiments were conducted in animals or humans. Informed consent was obtained from patients for the collection and study of pleural effusion samples.

Data availability. All RNA-Seq data sets generated as part of this study are publicly available at the European Nucleotide Archive ([https://www.ebi.ac.uk/ena](https://www.ebi.ac.uk/ena)), under accession number PRJEB30090.

Author contributions
RMC, CJL, and SPV conceived and designed the study. RMC, GM, DBK, JA, ANJT, AA, SJP, SH, AM, JCS, CJL, and SPV developed the methodology. RMC, DBK, JA, SJP, JCS, CJL, and SPV acquired data. RMC, GM, JA, SH, CJL, SPV, and AL analyzed and interpreted data (including statistical analysis, biostatistics, and computational analysis). All authors wrote, reviewed, and/or revised the manuscript.

Acknowledgments
This work was funded by program grants to SPV from Integrating Cancer Research Site (SIRIC) SOCRATE-2 INCa-DGOS-INSERM_12551 and ATIP-Avenir; program grants to CJL from Cancer Research UK and Breast Cancer Now, as well as a project grant to JCS from SIRIC-SOCRATE. RMC received funding from Fondation Philanthropia—Lombard Odier.

Address correspondence to: Sophie Postel-Vinay, DITEP, Gustave Roussy — 114, Rue Edouard Vaillant, 94805 Villejuif, France. Phone: 33.01.42.11.43.43; Email: sophie.postel-vinay@gustaveroussy.fr.

18. Erdal E, Haider S, Rehwinkel J, Harris AL, McHugh PJ. A prosurvival DNA damage-induced


